METHOD FOR DETECTING miRNA-206 FOR ANALYZING THE DIAGNOSIS OR PROGNOSIS OF A MENTAL ILLNESS BY A MOOD DISORDER, METHOD FOR PROVIDING INFORMATION FOR THE DIAGNOSIS, AND A COMPOSITION FOR TARGETING miRNA-206

• US 20180372722A1
• Filed: 10/21/2016
• Published: 12/27/2018
• Est. Priority Date: 12/17/2015
• Status: Abandoned Application

• Current Assignee: Advanced NT
• Original Assignee: Advanced NT
• Inventors: CHU, Kon, LEE, Sang Kun, KIM, Manho, JUNG, Keun-Hwa, LEE, Soon-Tae, JEON, Daejong
• Application Number:
  US16/063,558
• Publication Number:
  US 20180372722A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/712 Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: G01N 33/5023 on expression patterns

Abstract

The present invention relates to a method for detecting miRNA-206 for analyzing the diagnosis or prognosis of a mental illness by a mood disorder, a method for providing information for the diagnosis, and a composition for targeting miRNA-206, more specifically, the present invention can detect diagnosis or prognostic analysis marker of the said mental illness by a mood disorder, enable a more accurate diagnosis of a mental illness by a mood disorder by measuring the expression level of miR-206 from a tissue sample of a patient, provide a diagnostic composition capable of measuring the expression level of the said miR-206, and furthermore provide a pharmaceutical composition capable of treating and preventing a mental illness by a mood disorder by using an oligonucleotide that can bind complementary to microRNA-206.

Claims

1. A method for detecting diagnostic or prognostic marks of a mental illness by a mood disorder by using a method of detecting milt-206 expression to provide information necessary for diagnosis or prognosis analysis of a mental illness by a mood disorder.

2. The method for detecting diagnostic or prognostic marks of a mental illness by a mood disorder according to claim 1, wherein the said detecting miR-206 expression utilize a primer pair, a probe or an antisense nucleotide capable of complementarily binding to the said miR-206.

3. The method for detecting diapostic or prognostic marks of a mental illness by a mood disorder according to claim 1, wherein the said method of detecting milt-206 expression is the method using any one of reverse transcriptase polymerase, competitive reverse transcriptase polymerase, real-time reverse transcriptase polymerase, RNase protection assay, Northern Blotting or DNA chip.

4. The method for detecting diapostic or prognostic marks of a mental illness by a mood disorder according to claim 1, wherein the said mental illness by a mood disorder is depression, dysthymic disorder, depressive disorder, short-term depressive disorder, depressive disorder before menstrual and bipolar disorder.

5. A method of providing information for the diagnosis of a mental illness by a mood disorder comprising the step of:

measuring the expression level of miR-206 from a tissue sample of a patient; and

comparing the expression level of the said miR-206 with a reference level.

6. The method of providing information for the diagnosis of a mental illness by a mood disorder according to claim 5 further comprising the step of comparing the expression level of the said miR-206 with a reference level, and determining with a mental illness by a mood disorder when the said expression level is increased.

7. The method of providing information for the diagnosis of a mental illness by a mood disorder according to claim 5, wherein the said comparing step further uses at least one clinical information of age, sex, weight, diet, body mass, underlying disease, blood test result, brain MRI result, brain CT result or brain spinal fluid test result of the patient to determine a mental illness by a mood disorder.

8. The method of providing information for the diagnosis of a mental illness by a mood disorder according to claim 5, wherein the said expression level of miR-206 is measured by utilizing a primer pair, a probe or an antisense nucleotide capable of complementarily binding to the said miR-206.

9. The method of providing information for the diagnosis of a mental illness by a mood disorder according to claim 5, wherein the said method of measuring expression level of miR-206 is the method using any one of reverse transcriptase polymerase, competitive reverse transcriptase polymerase, real-time reverse transcriptase polymerase, RNase protection assay, Northern Blotting or DNA chip.

10. An agent for measuring the expression level of miR-206 which is a composition for diagnosing a mental illness by a mood disorder comprising a primer pair, a probe or an antisense nucleotide capable of complementarily binding to the said miR-206.

11. The kit for diagnosing a mental illness by a mood disorder comprising the composition for diagnosing according to claim 10.

12. A pharmaceutical composition for treating or preventing a mental illness by a mood disorder targeting miR-206.

13. The pharmaceutical composition for treating or preventing a mental illness by a mood disorder according to claim 12, wherein the substance targeting the said miR-206 comprises a nucleic acid molecule capable of binding to all or part of the nucleotide sequence of SEQ ID NO:

1 of the said miR-206.

14. The pharmaceutical composition for treating or preventing a mental illness by a mood disorder according to claim 13, wherein the said nucleic acid molecule is RNA, DNA, antagomir, antisense molecules, siRNA, shRNA, 2′

-O-modified oligonucleotide, phosphorothioate-backbone deoxyribonucleotide, phosphorothioate-backbone ribonucleotide, decoy oligonucleotide, PAN (peptide nucleic acid) oligonucleotide or LNA (locked nucleic acid) oligonucleotide.

15. The pharmaceutical composition for treating or preventing a mental illness by a mood disorder according to claim 12, wherein the composition targeting the said miR-206 is used for producing an agent capable of treating or preventing a mental illness by a mood disorder through an anxiety-restoring action.

16. The pharmaceutical composition for treating or preventing a mental illness by a mood disorder according to claim 12, wherein the composition targeting the said miR-206 is used for treating or preventing a mental illness by a mood disorder through an desperation-restoring action.

17. The pharmaceutical composition for treating or preventing a mental illness by a mood disorder according to claim 12, wherein the composition targeting the said miR-206 is utilized for producing an agent for treating or preventing a mental illness by a mood disorder through an action of inhibiting the expression or activity of miR-206.